EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
Decision brief
Answer first · skim in under a minute
EMA recommended datopotamab deruxtecan in Europe, but the supported EU approval in the evidence base is for HR-positive, HER2-negative breast cancer rather than lung cancer. In the U.S., DATROWAY has accelerated approval for EGFR-mutated NSCLC, making this a key catalyst-tracking update for BD teams and investors.
Datopotamab deruxtecan fda approval in the U.S. is for previously treated metastatic HR-positive, HER2-negative breast cancer (Jan. 17, 2025). EMA authorized Datroway for the same breast setting, while the EU non-small cell lung cancer application was withdrawn—so lung access remains unclear.
Contents10 sections
Key Takeaways
- FDA approved Datroway on Jan. 17, 2025 for unresectable/metastatic HR+/HER2− breast cancer after endocrine therapy and chemotherapy.
- TROPION-Breast01 showed median PFS 6.9 vs 4.9 months (HR 0.63); OS was not improved (HR 1.01).
- EMA marketing authorization for breast cancer followed on April 4, 2025 after a Jan. 30, 2025 CHMP positive opinion.
- The EU NSCLC filing was withdrawn Dec. 20, 2024; lung-cancer EU access is not approved.
What does datopotamab deruxtecan FDA approval cover?
FDA approved datopotamab deruxtecan-dlnk (Datroway) for adults with unresectable or metastatic HR-positive, HER2-negative breast cancer who already received endocrine-based therapy and chemotherapy for advanced disease.
Daiichi Sankyo said TROPION-Breast01 cut the risk of progression or death by 37% versus investigator’s-choice chemotherapy (HR 0.63; 95% CI 0.52–0.76). Median PFS was 6.9 versus 4.9 months. See the Daiichi Sankyo U.S. approval release.
Did overall survival improve?
No. An FDA approval summary in Clinical Cancer Research reports median OS of 18.6 months with Datroway versus 18.3 months with chemotherapy (HR 1.01; 95% CI 0.83–1.22). The OS endpoint was not met.
Confirmed ORR was 36% versus 23%, with median duration of response 6.7 versus 5.7 months. Common adverse reactions (≥20%) included stomatitis, nausea, fatigue, alopecia, constipation, dry eye, keratitis, and vomiting. Trial ID: NCT05104866 (TROPION-Breast01).
- PFS HR 0.63 (6.9 vs 4.9 months)
- OS HR 1.01 (18.6 vs 18.3 months)
- ORR 36% vs 23%
What did EMA decide on breast vs lung?
EMA’s Datroway EPAR lists EU marketing authorization on April 4, 2025 for adult HR-positive, HER2-negative unresectable or metastatic breast cancer after endocrine therapy and at least one chemotherapy line in the advanced setting.
Separately, Daiichi Sankyo withdrew the Datopotamab deruxtecan Daiichi Sankyo NSCLC application on Dec. 20, 2024 after CHMP concerns. EMA’s withdrawal page states the provisional view was that authorization for NSCLC could not be granted. Read the EMA Datroway medicine page and the EMA NSCLC withdrawal page.
Why lung-cancer access still looks unclear
EU lung filing withdrawal means there is no Datroway NSCLC marketing authorization in Europe from that application. Ongoing Phase 3 lung studies may still read out elsewhere, but they do not restore the withdrawn EU file.
For U.S. teams, the near-term labeled use to track is the breast indication tied to TROPION-Breast01, not an assumed lung label.
How to read the slug versus the evidence
The article URL still mentions lung-cancer access because that was an earlier narrative hook. The sourced European record is clearer: breast cancer is authorized; the NSCLC file was withdrawn in December 2024.
U.S. datopotamab deruxtecan fda approval language should stay tied to the HR-positive, HER2-negative breast label unless a later lung indication is granted and cited from FDA or a wire. Do not infer EU lung access from U.S. breast approval, or the reverse.
Sponsors still run multi-tumor Phase 3 programs. Those trials can change the story later, but they do not rewrite today’s approved labels.
What remains unproven
OS benefit is unproven in the breast approval package. Cross-tumor “access” claims that blur breast approval with lung filings are inaccurate for both FDA and EMA records.
Payer uptake will also depend on stomatitis and ocular adverse-event management, not PFS alone. For EU launch planning, map Datroway to the breast EPAR indication and treat NSCLC as withdrawn unless a new application is filed and reviewed.
Related NovaPharma coverage
- Datopotamab deruxtecan drug profile
- Daiichi Sankyo company profile
- AstraZeneca company profile
- FDA approves Vertex Journavx
Frequently Asked Questions
What is the datopotamab deruxtecan FDA approval?
On Jan. 17, 2025, FDA approved Datroway (datopotamab deruxtecan-dlnk) for unresectable or metastatic HR-positive, HER2-negative breast cancer after prior endocrine therapy and chemotherapy.
Did EMA approve Datroway for lung cancer?
No. Daiichi Sankyo withdrew its EU NSCLC marketing application on Dec. 20, 2024. EMA later authorized Datroway for HR-positive, HER2-negative breast cancer on April 4, 2025.
What did TROPION-Breast01 show?
Median PFS was 6.9 months with Datroway versus 4.9 months with investigator’s-choice chemotherapy (HR 0.63). Overall survival was not improved (median 18.6 vs 18.3 months; HR 1.01).
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for datopotamab deruxtecan.
Unlock full calendar →AstraZeneca pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
Deeper reading
Industry reports & whitepapers
- Radiation Therapy: Fractionation, Image-Guidance, and Special Services (Idaho Only) — This policy outlines medically necessary radiation therapy protocols for conditions like breast canc…